The goal of this observational study is to evaluate patient outcomes following treatment of vertebrogenic low back pain using the Stryker OptaBlate BVN System. Patients treated in accordance with the device IFU as part of routine clinical care and who consent to participate will be followed for 12 months after the procedure to assess treatment outcomes.

Inclusion Criteria:

• Patient scheduled for treatment with the OptaBlate BVN System in accordance with the device IFU and willing to participate in the clinical investigation, undergo study procedure, engage in follow-up, able to read, write, speak, and understand English, and able to provide written informed consent.

Exclusion Criteria:

• The patient meets one or more contraindications as defined in the locally applicable IFU
• Spinal fracture or history of spinal trauma at index levels
• Previous lumbar fusion at any level
• Prior basivertebral nerve ablation at the target levels
• Vertebral cancer, spinal metastasis or Tumor-related vertebral fractures
• History of Osteoporotic vertebral fractures
• Spine interventions, including epidural steroid injections within 30 days
• BMI > 40 kg/m²
• Symptomatic spinal stenosis
• Radicular pain or leg pain greater than back pain
• Pregnancy or planning pregnancy during study period
• Enrollment in another interventional clinical trial
• Contraindication to MRI
• Life expectancy of less than 12 months

Patients with chronic low back pain of at least 6 months' duration that has not responded to at least 6 months of conservative treatment and who demonstrate Type 1 or Type 2 Modic changes on MRI consistent with vertebrogenic pain.

Individual participant data will not be shared to protect patient confidentiality and because data sharing is not included in the informed consent or study protocol